Soft Tissue Sarcoma with Jonathan C. Trent, MD, PhD and Shreyaskumar R. Patel, MD: Case 1 - Episode 10
How has the availability of targeted therapies influenced treatment options for patients with leiomyosarcoma?
This patient has received first-, second-, and third-line chemotherapy regimens that are standard of care for patients with advanced leiomyosarcoma. A newer agent, termed trabectedin, has been shown in a randomized study to be superior to dacarbazine in terms of progression-free survival.
In this patient, I would use as the next line of therapy trabectedin, given as 1.5 m/g2continuous infusion every 3 weeks.
CASE: Soft-Tissue Sarcoma (Part 1)
Rachel F is a 58-year-old school teacher from Roanoke, Virginia. Her medical history is notable for mild hypertension and total knee replacement in 2011
Follow-up CT scan in January 2014 showed progression at multiple sites; at the time of follow up, her ECOG performance status was 1, with renal and hepatic function within normal limits
In September of 2014 she returns for follow-up, unable to work with increasing fatigue and abdominal pain, and her CT scan was consistent with progressive disease
After 4 months of therapy, she presents with worsening abdominal pain and declining performance status